key: cord-1005935-x2u1e26r
authors: Wegrzyn, R. D.; Appiah, G. D.; Morfino,; R., Milford; S. R., Walker; A. T., Ernst; E. T., Darrow; W. W., Li; S. L., Robison; K., MacCannell; D., Dai; D., Girinathan; B. P., Hicks; A. L., Cosca; B., Woronoff; G., Plocik; A. M., Simen; B. B., Moriarty; L., Guagliardo; S. A. J., Cetron; M. S., Friedman; C., R.
title: Early detection of SARS-CoV-2 variants using traveler-based genomic surveillance at four US airports, September 2021- January 2022
date: 2022-03-22
journal: nan
DOI: 10.1101/2022.03.21.22272490
sha: 5e5cd326eef0cd3324d3ba3c7aae91f9ae4f3967
doc_id: 1005935
cord_uid: x2u1e26r

We enrolled arriving international air travelers in SARS-CoV-2 genomic surveillance, using molecular testing of pooled nasal swabs, and sequencing positive samples for viral lineage. Traveler-based genomic surveillance provided early warning variant detection; we reported the first U.S. Omicron BA.2 and first BA.3 in North America, weeks before next reported detection.

Background Despite layered mitigation measures, international travel during the COVID-19 pandemic continues to facilitate global spread of SARS-CoV-2, including novel variants of concern (VOCs). On November 26, 2021, B.1.1.529 (Omicron) was designated as a VOC by the World Health Organization [1] . On December 6, 2021, as part of measures to reduce the introduction and spread of Omicron, the requirement for a negative SARS-CoV-2 test taken before air travel to the United States was shortened from three days to one day pre-departure [1] . Although SARS-CoV-2 genomic sequencing has increased significantly during the pandemic [2] , there is still a gap in early detection of emerging variants among arriving travelers.

In September 2021, the Centers for Disease Control and Prevention (CDC), in collaboration with private partners, implemented a voluntary SARS-CoV-2 genomic surveillance pilot program.

Initially we enrolled arriving air travelers from India. On November 28, we expanded the program to include travelers arriving from countries with high travel volumes, including those where Omicron was first detected.

During September 29-November 27, 2021, the surveillance program included travelers arriving on seven direct flights from India at three international airports: John F. Kennedy, New York (September 29), Newark Liberty, New Jersey (October 4), and San Francisco, California

Amplicons were pooled and prepared using standard protocols. For Illumina sequencing, samples underwent tagmentation and were sequenced on NovaSeq 6000 (2x50 bp; Illumina). For rapid lineage identification, a ligation-based library was prepared and sequenced on GridION (Oxford Nanopore) as described in supplemental methods.

Travelers participating in pooled testing were advised to submit their at-home kit for individual testing. Individual test results were reported to participants via a secure digital portal and to public health authorities per CDC reporting guidelines [5] . Sequencing data were provided to CDC for viral culture and characterization and uploaded to the Global Initiative on Sharing Avian Influenza Data (GISAID) public database.

For this analysis we focused on the effectiveness of pooled testing for early variant detection and thus included pooled testing results only. Using Fisher's exact tests, we assessed differences in pooled positivity rates across two collection periods (September 29-November 27 and November 28-January 23) and by flight country of origin. Statistical analysis was conducted in Figure 1b) . Similarly, a sample collected on December 3 was the first reported BA.3 in North America, 43 days before the next report [6] .

This traveler-based SARS-CoV-2 genomic surveillance program was able to identify importation of variants, including Omicron sub-lineages BA.2 and BA.3 at 7 and 43 days before they were reported elsewhere in the United States and North America, respectively. Overall, 16% of pooled tests were positive, with 21% positivity following Omicron emergence. We detected an increased number of positive post-arrival pooled samples after December 6, when air passengers were required to have a negative sample collected within one day before flight departure.

Possible reasons for high pooled test-positivity on arrival despite negative pre-departure testing include timing of infection (i.e., before infection can be detected by available testing), use of certain testing modalities with lower sensitivity [7] , or infection soon after pre-departure sample collection [8, 9] . If passengers had infections that were not yet detected in pre-departure testing, longer flight times may have led to detection of more positive tests on arrival [9]. Many of our positive pools were from flights over 16 hours long. Finally, it is possible that fraudulent test results were presented to meet the pre-departure testing requirement [10].

Pooled testing in this program is advantageous as it enables efficient, large volume sampling and increases testing throughput while conserving resources. This can be valuable for continued detection when prevalence of SARS-CoV-2 infection is low. The pooled testing design minimizes dilution and reduces loss of sensitivity by pooling dry swabs at the point of collection Each Concentric network laboratory is validated to ensure molecular assay sensitivity of 1,500 viral copies/mL. The disadvantage of pooled testing is an inability to directly link test results with individual-level data. Follow-up individual testing, such as the at-home test kits collected in our program (data not presented), provide an additional opportunity to capture linkable meta-data.

With~ 10% participation rate, we were able to detect the first Omicron sub-lineages BA.2 and BA.3 not previously reported in the United States or North America, weeks before they were reported by other US and North American sequencing efforts. The country-level proportions of variants that we identified were consistent with those reported by national and global sequencing programs [2] . Our study suggests that when COVID-19 rates are high, as during the Omicron surge, a 10% participation rate would be sufficient to detect relatively rare variant sublineages.

As COVID-19 rates decline in the post-Omicron period, the program could shift to population-level genomic surveillance techniques that are not reliant on passenger participation such as wastewater or air sampling from aircraft environments to increase variant detection.

Detection of imported emerging infectious diseases has traditionally focused on travelers presenting to health clinics after symptom onset [12] . COVID-19 presents unique challenges since transmission often occurs before symptom onset or in asymptomatic infected persons [7] .

By the time variants are detected there is often widespread community transmission. Many countries have required testing for arriving travelers to limit introduction and spread of SARS-CoV-2 [11] yet few utilize traveler-based viral genomic surveillance to detect new variants and provide more detailed epidemiological data. Earlier detection of new SARS-CoV-2 variants of interest and concern allows researchers and public health officials the needed time to gather information about transmissibility, virulence, and vaccine effectiveness to enable adjustments to treatment and prevention strategies [2] . This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 22, 2022. ;

This traveler-based genomic surveillance program underscores the importance of public-private partnerships in achieving public health priorities in an ever-changing pandemic, and the utility of surveillance tools beyond traditional individual testing. The program's scalability and adaptability, including the ability to rapidly add locations and expedite sequencing, were key factors for success. Traveler-based SARS-CoV-2 genomic surveillance provides a model of pathogen detection that can be used as an early warning, sentinel system for future outbreaks affecting international travelers or pandemics.

Prevention contract award number 75D30121C12036.

The authors acknowledge no conflicts of interest, relevant financial interests, activities, relationships, and affiliations exist.

health authorities -who supported the operational implementation of the program on the ground in airports.

The findings and conclusions of this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. This activity was conducted in partnership with commercial partners, Xprescheck and Concentric by Ginkgo.

The use of products' or services' names is for identification purposes and does not mean endorsement by the Centers for Disease Control and Prevention. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 14 for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Passengers and flight crew arriving from pre-selected international destinations were invited to participate in the voluntary program at one of four US international airports. During September 29-November 27, flight crew announced the program during selected international flights from India using a provided script and directed passengers to informational brochures. During November 28-January 23, in-flight announcements were not used as pooled samples were grouped by country of origin rather than flight. During both enrollment periods, program information and booths were placed in a strategic location at each airport, in the arrivals area near baggage claim, to engage interested arriving travelers. Guidance for collection of dry nasal swab and saliva self-collection samples were provided in technical instructions [1] [2] .

We estimated the total number of eligible participants on pre-selected international flights using the following methodology: for a sample week, we reviewed the flight numbers indicated on the program pamphlet by the participants and estimated the total number of eligible passengers assuming ~200 passengers per flight. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Reverse transcribed RNA was amplified using the ARTICv3 protocol [3] . Amplicons were pooled and prepared for library preparation using standard protocols. For Illumina sequencing, samples underwent tagmentation and were sequenced on NovaSeq 6000 (2x50 bp; Illumina). For rapid lineage identification, a ligation-based library was prepared and sequenced on GridION (Oxford Nanopore). With SARS-CoV-2 genome MN908947.3 as reference, Illumina data was aligned with BWA-MEM and Guppy-called Nanopore data with minimap2 (using ont-map option). Variant Call Format (VCF) files were generated with FreeBayes [4] (Illumina) or medaka-variant (Nanopore) and these VCF files used in both cases to generate consensus sequences with bcftools. Lineages were called from consensus sequences with pangolin v3.1.16 [5] using the sarscov2_lineages workflow on the Terra platform [6]. Variant lineages were not assigned for sequences that did not meet pangolin minimum length of 10,000 bases and <50% N (unassigned) bases. Clade assignments, reference-based QC calls, mutational profiles, and associated visualizations for analyses were produced through the Nextclade webserver v1.8.1 [7] .

The presence or absence of minor variant strains was assessed through analysis of alternate allele frequencies in the Illumina data set generated by both FreeBayes (v1.3.1) and iVar (v1.3.1). For mixed samples, lineage deconvolution was performed using two independent workflows: LCS (https://arxiv.org/abs/2110.01117v1) and Freyja (https://www.medrxiv.org/content/10.1101/2021.12.21.21268143v1.full.pdf).

for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

SARS-CoV-2 B. 1.1. 529 (Omicron) Variant-United States

Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B. 1.617. 2) and Omicron (B. 1.1. 529) Variants-United States

Thermo Fisher Scientific Confirms Detection of SARS-CoV-2 in Samples Containing the Omicron Variant with its TaqPath COVID-19 Tests

Patient Self-Collection Kit and Collection Process Standard Operating Procedures

Improvements to the ARTIC multiplex PCR method for SARS-CoV-2 genome sequencing using nanopore

Haplotype-based variant detection from short-read sequencing

Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool

Nextclade: clade assignment, mutation calling and quality control for viral genomes

The authors would like to thank the entire XpresCheck 

Abbreviations: ATL, Hartsfield-Jackson Atlanta International Airport; EWR, Newark Liberty International Airport; JFK, John F. Kennedy International Airport; SFO, San Francisco International Airport; SGTF, S-Gene Target Failure; VOC, Variants of concern; WHO, World Health Organization